Matthew Sykes
Stock Analyst at Goldman Sachs
(3.85)
# 669
Out of 4,749 analysts
195
Total ratings
52.24%
Success rate
8.67%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NEO NeoGenomics | Maintains: Buy | $20 → $18 | $14.86 | +21.17% | 6 | Jan 28, 2025 | |
| NTRA Natera | Maintains: Buy | $160 → $190 | $172.66 | +10.05% | 13 | Jan 28, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $29 → $18 | $12.62 | +42.63% | 10 | Jan 28, 2025 | |
| GH Guardant Health | Maintains: Buy | $36 → $49 | $49.18 | -0.37% | 12 | Jan 28, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $2.25 → $1.75 | $1.58 | +11.11% | 4 | Jan 23, 2025 | |
| CRL Charles River Laboratories International | Maintains: Buy | $220 → $190 | $163.62 | +16.12% | 3 | Jan 23, 2025 | |
| NAUT Nautilus Biotechnology | Downgrades: Sell | $2.25 → $1.75 | $1.77 | -1.13% | 5 | Dec 5, 2024 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Sell | $7 → $4.25 | $5.05 | -15.76% | 10 | Dec 5, 2024 | |
| VCYT Veracyte | Downgrades: Neutral | $38 → $37 | $46.53 | -20.47% | 5 | Dec 5, 2024 | |
| BRKR Bruker | Upgrades: Neutral | $60 | $55.99 | +7.16% | 4 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $55.66 | +16.78% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $200.48 | +24.70% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $54 → $70 | $80.96 | -13.54% | 10 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $14 | $15.17 | -7.71% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $280 | $200.93 | +39.35% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $35 | $22.97 | +52.37% | 9 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $23 | $16.83 | +36.66% | 2 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $250 | $224.37 | +11.42% | 4 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $55 | $51.30 | +7.21% | 9 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $6.5 | $19.80 | -67.17% | 11 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $9.48 | +153.30% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,365.82 | -4.82% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $12.47 | -3.77% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $603.95 | +5.97% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $5.74 | +74.22% | 8 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $22.02 | +18.10% | 5 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $151.12 | -4.05% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $44.65 | - | 5 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $105 | $127.00 | -17.32% | 1 | Oct 31, 2023 |
NeoGenomics
Jan 28, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $14.86
Upside: +21.17%
Natera
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $172.66
Upside: +10.05%
Myriad Genetics
Jan 28, 2025
Maintains: Buy
Price Target: $29 → $18
Current: $12.62
Upside: +42.63%
Guardant Health
Jan 28, 2025
Maintains: Buy
Price Target: $36 → $49
Current: $49.18
Upside: -0.37%
Pacific Biosciences of California
Jan 23, 2025
Maintains: Neutral
Price Target: $2.25 → $1.75
Current: $1.58
Upside: +11.11%
Charles River Laboratories International
Jan 23, 2025
Maintains: Buy
Price Target: $220 → $190
Current: $163.62
Upside: +16.12%
Nautilus Biotechnology
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $1.77
Upside: -1.13%
Maravai LifeSciences Holdings
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $5.05
Upside: -15.76%
Veracyte
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $46.53
Upside: -20.47%
Bruker
Dec 5, 2024
Upgrades: Neutral
Price Target: $60
Current: $55.99
Upside: +7.16%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $55.66
Upside: +16.78%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $200.48
Upside: +24.70%
Oct 30, 2024
Maintains: Neutral
Price Target: $54 → $70
Current: $80.96
Upside: -13.54%
Oct 30, 2024
Maintains: Sell
Price Target: $16 → $14
Current: $15.17
Upside: -7.71%
Oct 25, 2024
Maintains: Buy
Price Target: $370 → $280
Current: $200.93
Upside: +39.35%
Oct 16, 2024
Maintains: Buy
Price Target: $26 → $35
Current: $22.97
Upside: +52.37%
Oct 8, 2024
Maintains: Neutral
Price Target: $26 → $23
Current: $16.83
Upside: +36.66%
Jul 24, 2024
Maintains: Neutral
Price Target: $225 → $250
Current: $224.37
Upside: +11.42%
Jul 9, 2024
Maintains: Buy
Price Target: $45 → $55
Current: $51.30
Upside: +7.21%
Jul 9, 2024
Maintains: Neutral
Price Target: $23 → $6.5
Current: $19.80
Upside: -67.17%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $9.48
Upside: +153.30%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,365.82
Upside: -4.82%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $12.47
Upside: -3.77%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $603.95
Upside: +5.97%
Feb 29, 2024
Maintains: Buy
Price Target: $9 → $10
Current: $5.74
Upside: +74.22%
Dec 7, 2023
Maintains: Buy
Price Target: $23 → $26
Current: $22.02
Upside: +18.10%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $151.12
Upside: -4.05%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $44.65
Upside: -
Oct 31, 2023
Maintains: Buy
Price Target: $120 → $105
Current: $127.00
Upside: -17.32%